Clinical Trial Detail

NCT ID NCT02201992
Title Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Eastern Cooperative Oncology Group
Indications

lung non-small cell carcinoma

Therapies

Crizotinib

Age Groups: adult

No variant requirements are available.